Harnessing the Power of Radiopharmaceuticals

Engineered molecules

Our bespoke, iterative approach to radiotherapeutic design is fueled by a toolbox of technologies for peptide-based radiopharmaceuticals.

Learn Our Approach

Our pipeline

We are developing a robust pipeline of radiopharmaceuticals to address targets spanning solid and hematologic malignancies.

View Our Pipeline

Industry-leading team

Backed by top-tier investors, our team has decades of expertise developing radiopharmaceuticals for highly targeted treatment of cancer.

Meet the Team

News & Events

January 30, 2024

ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program

GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech...

January 8, 2024

NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225 (Ac-225)

Long term, multi-year supply agreement provides Alpha-9 with NorthStar’s high purity non-carrier added (n.c.a.) Ac-225 to be used in Alpha-9’s targeted radiopharmaceutical...

March 7, 2023

Alpha-9 Theranostics Strengthens its Scientific Expertise with Key Appointments to Leadership Team and Scientific Advisory Board

Dr. Jutta Wanner to lead R&D discovery efforts and support the continued expansion of Alpha-9’s differentiated radiopharmaceutical pipeline Dr. Jason Lewis and...